These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2921099)

  • 1. Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test.
    Saudek F; Morávek J; Modr Z
    Int J Clin Pharmacol Ther Toxicol; 1989 Feb; 27(2):82-7. PubMed ID: 2921099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indocyanine green clearance test and model for end-stage liver disease score of patients with liver cirrhosis.
    Sheng QS; Lang R; He Q; Yang YJ; Zhao DF; Chen DZ
    Hepatobiliary Pancreat Dis Int; 2009 Feb; 8(1):46-9. PubMed ID: 19208514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normal metabolism of morphine in cirrhosis.
    Patwardhan RV; Johnson RF; Hoyumpa A; Sheehan JJ; Desmond PV; Wilkinson GR; Branch RA; Schenker S
    Gastroenterology; 1981 Dec; 81(6):1006-11. PubMed ID: 7286578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Half-life time or clearance of indocyanine green in patients with liver disease.
    Gilmore IT; Marigold JH; Thompson RP
    Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetic study of a cephalosporin, cefoperazone, in liver failure].
    Belaieff J; Cochet B; Allaz AF; Rudhardt M; Balant L; Fabre J
    Schweiz Med Wochenschr; 1981 Apr; 111(14):502-8. PubMed ID: 6453423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of famotidine after intravenous administration in liver disease.
    Ohnishi K
    Am J Gastroenterol; 1991 Jan; 86(1):41-5. PubMed ID: 1986553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel galactose single point method as a measure of residual liver function: example of cefoperazone kinetics in patients with liver cirrhosis.
    Hu OY; Tang HS; Chang CL
    J Clin Pharmacol; 1995 Mar; 35(3):250-8. PubMed ID: 7608313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of cefoperazone in healthy volunteers.
    Saudek F; Morávek J; Modr Z
    Czech Med; 1986; 9(3):162-5. PubMed ID: 3095076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic study on the hepatic uptake of indocyanine green in cirrhotic patients.
    Kawasaki S; Sugiyama Y; Iga T; Hanano M; Sanjo K; Beppu T; Idezuki Y
    Am J Gastroenterol; 1985 Oct; 80(10):801-6. PubMed ID: 4036939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function.
    Wensing G; Lotterer E; Link I; Hahn EG; Fleig WE
    Hepatology; 1997 Nov; 26(5):1149-55. PubMed ID: 9362355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic metabolic function in patients receiving long-term methotrexate therapy: comparison with topically treated psoriatics, patient controls and cirrhotics.
    Birnie GG; Fitzsimons CP; Czarnecki D; Cooke A; Scobie G; Brodie MJ
    Hepatogastroenterology; 1985 Aug; 32(4):163-7. PubMed ID: 2865199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temazepam clearance unaltered in cirrhosis.
    Ochs HR; Greenblatt DJ; Verburg-Ochs B; Matlis R
    Am J Gastroenterol; 1986 Jan; 81(1):80-4. PubMed ID: 2867675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of triglycyl-lysin-vasopressin on quantitative liver function tests in patients with cirrhosis.
    Merkel C; Bianco S; Bolognesi M; Caregaro L; Amodio P; Sacerdoti D; Gatta A
    Am J Gastroenterol; 1992 Nov; 87(11):1580-6. PubMed ID: 1442677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Liver metabolism of indocyanine green and aminopyrine in liver cirrhosis: relations with functioning liver cell mass].
    Bolognesi M; Merkel C; Angeli P; Caregaro L; Gatta A
    Minerva Med; 1988 Dec; 79(12):1035-41. PubMed ID: 3211355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in metildigoxin pharmacokinetics in cirrhosis of the liver: a comparison with beta-acetyldigoxin.
    Rameis H; Woodcock B; Bonelli J; Waginger H
    Int J Clin Pharmacol Ther Toxicol; 1984 Mar; 22(3):145-51. PubMed ID: 6715083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranitidine disposition in severe hepatic cirrhosis.
    Gonzalez-Martin G; Paulos C; Veloso B; Chesta J; Novoa X; Arancibia A
    Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):139-42. PubMed ID: 3557740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetic study of a cephalosporin: cefoperazone in patients with a Kehr drain].
    Farquet C; Marti MC; Balant L; Cochet B; Rudhardt M; Fabre J; Rohner A
    Schweiz Med Wochenschr; 1982 Jan; 112(4):123-9. PubMed ID: 6461067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of iloprost in patients with hepatic dysfunction.
    Hildebrand M; Krause W; Angeli P; Koziol T; Gatta A; Merkel C; Bolognesi M
    Int J Clin Pharmacol Ther Toxicol; 1990 Oct; 28(10):430-4. PubMed ID: 1701761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition of nafcillin in patients with cirrhosis and extrahepatic biliary obstruction.
    Marshall JP; Salt WB; Elam RO; Wilkinson GR; Schenker S
    Gastroenterology; 1977 Dec; 73(6):1388-92. PubMed ID: 913979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of cimetidine in patients with liver disease.
    González-Martin G; Arancibia A; Fajuri M; Chesta J; Novoa X
    Int J Clin Pharmacol Ther Toxicol; 1985 Jul; 23(7):355-8. PubMed ID: 4030163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.